EN

Enveric Biosciences Inc

ENVB
Accountable AI Logo

Enveric Biosciences Inc AI Insights

Informational only. Not investment advice.
As of 2025-12-11

Snapshot

  • Zero revenue pre-clinical biotech burning 7.7M TTM cash with only 3.8M remaining - ~6 month runway without dilution[Cash and Equivalents]
  • Market cap of 142K vs book value of 3.5M yields P/B of 0.04x - trading at 96% discount to tangible assets[Price to Book Ratio]
  • R&D spend of 3.4M TTM is just 7.5% of industry median (45M) - minimal pipeline investment capacity[Research and Development]

Watch Triggers

  • Cash and Equivalents: Falls below 2M or rises above 10MBelow 2M = imminent dilution; above 10M = successful raise extending runway
  • Shares Outstanding: Increases >50% from 26K baseSignals magnitude of dilution - each doubling halves existing holder value
  • Research and Development: Quarterly spend exceeds 1.5MWould indicate accelerated pipeline activity but faster cash depletion

Bull Case

Negative EV of -3.6M means cash exceeds market cap - any pipeline success creates asymmetric upside from near-zero base

Enterprise ValueCash and Equivalents

Zero debt (D/E: 0) and 3.3M working capital provide clean balance sheet for potential strategic transaction

Debt to EquityWorking Capital

Bear Case

6-month cash runway with -7.7M annual burn guarantees dilution; 26K shares could multiply 10x+ to fund operations

Free Cash Flow TTMCash and EquivalentsShares Outstanding

R&D of 3.4M is insufficient for meaningful clinical progress - underfunded vs 45M industry median

Research and DevelopmentTotal Revenue TTM

Bull vs Bear Balance

AI-generated sentiment analysis based on fundamental metrics and market conditions.

BearBull
20%

Leverage ENVB's top insights and create a custom strategy based on them in seconds. Our AI editor does it all — in one click.

Take Me to The Editor

Forward Thesis

Imminent dilution or reverse split required within 6 months to fund operations

3-12mhigh
  • Cash burn of 7.7M/year vs 3.8M cash
  • Zero revenue generation
  • 1.1M raised TTM insufficient
FCF TTM: -7.7MCash: 3.8MIssuance of Capital Stock: 1.1M

Extreme valuation discount suggests market pricing in near-certain failure or massive dilution

3-12mhigh
  • P/B of 0.04x vs positive equity
  • Negative enterprise value (-3.6M)
Market Cap: 142KBook Value: 3.5MEnterprise Value: -3.6M
Valuation Context
Caveats

Public Strategies Rankings

See how Enveric Biosciences Inc ranks across different investment strategies.

Leverage ENVB's top insights and create a custom strategy in seconds. Our AI editor does it all — in one click.

Data Partners
Morningstar Logo

Fundamental company data provided by Morningstar, updated daily.

Accountable Finance, Inc. Disclaimer
accountable.finance is not operated by a broker or a dealer. Under no circumstances does any information posted on accountable.finance represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. In no event shall accountable.finance be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on accountable.finance, or relating to the use of, or inability to use, accountable.finance or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. Stock quotes and fundamental company data provided by Morningstar, updated daily.

Accountable Logo
© 2025 Accountable Finance, Inc. All rights reserved.